287 related articles for article (PubMed ID: 34678198)
1. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Shakya M; Voysey M; Theiss-Nyland K; Colin-Jones R; Pant D; Adhikari A; Tonks S; Mujadidi YF; O'Reilly P; Mazur O; Kelly S; Liu X; Maharjan A; Dahal A; Haque N; Pradhan A; Shrestha S; Joshi M; Smith N; Hill J; Clarke J; Stockdale L; Jones E; Lubinda T; Bajracharya B; Dongol S; Karkey A; Baker S; Dougan G; Pitzer VE; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
Lancet Glob Health; 2021 Nov; 9(11):e1561-e1568. PubMed ID: 34678198
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Theiss-Nyland K; Shakya M; Colin-Jones R; Voysey M; Smith N; Karkey A; Dongol S; Pant D; Farooq YG; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ
Clin Infect Dis; 2019 Mar; 68(Suppl 2):S67-S73. PubMed ID: 30845329
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
[TBL] [Abstract][Full Text] [Related]
6. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
Patel PD; Liang Y; Meiring JE; Chasweka N; Patel P; Misiri T; Mwakiseghile F; Wachepa R; Banda HC; Shumba F; Kawalazira G; Dube Q; Nampota-Nkomba N; Nyirenda OM; Girmay T; Datta S; Jamka LP; Tracy JK; Laurens MB; Heyderman RS; Neuzil KM; Gordon MA;
Lancet; 2024 Feb; 403(10425):459-468. PubMed ID: 38281499
[TBL] [Abstract][Full Text] [Related]
8. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
Yousafzai MT; Karim S; Qureshi S; Kazi M; Memon H; Junejo A; Khawaja Z; Ur Rehman N; Ansari MS; Ali R; Ujjan IU; Lohana HM; Memon NM; Hussain M; Nigar R; Bar-Zeev N; Qamar FN
Lancet Glob Health; 2021 Aug; 9(8):e1154-e1162. PubMed ID: 34297962
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
Nampota-Nkomba N; Nyirenda OM; Khonde L; Mapemba V; Mbewe M; Ndaferankhande JM; Msuku H; Masesa C; Misiri T; Mwakiseghile F; Patel PD; Patel P; Johnson-Mayo I; Pasetti MF; Heyderman RS; Tracy JK; Datta S; Liang Y; Neuzil KM; Gordon MA; Laurens MB;
Lancet Glob Health; 2022 Sep; 10(9):e1326-e1335. PubMed ID: 35961356
[TBL] [Abstract][Full Text] [Related]
12. The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
Kulkarni PS; Potey AV; Bharati S; Kunhihitlu A; Narasimha B; Yallapa S; Dharmadhikari A; Gavade V; Kamat CD; Mallya A; Sarma AD; Goel S; Pisal SS; Poonawalla CS; Venkatesan R; Jones E; Flaxman A; Kim YC; Pollard AJ;
Lancet; 2024 Apr; 403(10436):1554-1562. PubMed ID: 38555928
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
15. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper.
Laurens MB; Sirima SB; Rotrosen ET; Siribie M; Tiono A; Ouedraogo A; Liang Y; Jamka LP; Kotloff KL; Neuzil KM
Clin Infect Dis; 2019 Mar; 68(Suppl 2):S59-S66. PubMed ID: 30845330
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial.
Theiss-Nyland K; Qadri F; Colin-Jones R; Zaman K; Khanam F; Liu X; Voysey M; Khan A; Hasan N; Ashher F; Farooq YG; Pollard AJ; Clemens JD
Clin Infect Dis; 2019 Mar; 68(Suppl 2):S74-S82. PubMed ID: 30845333
[TBL] [Abstract][Full Text] [Related]
18. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
Voysey M; Pollard AJ
Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis.
Batool R; Qamar ZH; Salam RA; Yousafzai MT; Ashorn P; Qamar FN
Lancet Glob Health; 2024 Apr; 12(4):e589-e598. PubMed ID: 38485426
[TBL] [Abstract][Full Text] [Related]
20. Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data.
Liang Y; Driscoll AJ; Patel PD; Datta S; Voysey M; French N; Jamka LP; Henrion MYR; Ndeketa L; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM
Lancet Glob Health; 2023 Jan; 11(1):e136-e144. PubMed ID: 36442498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
